ET-02 is under clinical development by EdiGene and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ET-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ET-02 is under development for the treatment of relapsed and refractory B-cell acute lymphocytic leukemia (ALL), non-Hodgkin lymphoma (NHL). It is a universal chimeric antigen receptor T cell therapy (U-CAR-T). The therapy is developed using CRISPR/Cas9 gene-editing platform technology.
EdiGene is a China-based biotechnology company. The company develops genome editing technologies for a range of diseases and provides creative solutions to advance drug discovery.
For a complete picture of ET-02’s drug-specific PTSR and LoA scores, buy the report here.